GlaxoSmithKline PLC ADR is a drug manufacturers - general business with stocks listed in the US. GlaxoSmithKline shares (GSK) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was US$35.99 – an increase of 0.5% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Low costs
Our top pick for
Dividend investing
GlaxoSmithKline's shares were split on a 1226:1000 basis on 22 July 2022. So if you had owned 1000 shares the day before the split, the next day you would own 1226 shares. This wouldn't directly have changed the overall worth of your GlaxoSmithKline shares – just the quantity. However, indirectly, the new 18.4% lower share price could have impacted the market appetite for GlaxoSmithKline shares which in turn could have impacted GlaxoSmithKline's share price.
| 52-week range | US$32.2211 - US$38.1993 |
|---|---|
| 50-day moving average | US$35.954 |
| 200-day moving average | US$35.5065 |
| Target price | US$39.88 |
| PE ratio | 9.6523 |
| Dividend yield | US$0.558 (3.91%) |
| Earnings per share (TTM) | US$3.71 |
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $35.99
| 1 week (2023-11-24) | 0.50% |
|---|---|
| 1 month (2023-11-02) | 5.33% |
| 3 months (2023-09-01) | 2.74% |
| 6 months (2023-06-02) | 5.51% |
| 1 year (2022-12-02) | 1.81% |
|---|---|
| 2 years (2021-12-02) | 6.40% |
| 3 years (2020-12-02) | 17.98% |
| 5 years (2018-11-30) | 5.38% |
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing GlaxoSmithKline stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of GlaxoSmithKline's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
GlaxoSmithKline's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 10x. In other words, GlaxoSmithKline shares trade at around 10x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
GlaxoSmithKline's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.1245. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into GlaxoSmithKline's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
GlaxoSmithKline's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$9.2 billion (£7.2 billion).
The EBITDA is a measure of a GlaxoSmithKline's overall financial performance and is widely used to measure a its profitability.
Over the last 12 months, GlaxoSmithKline's shares have ranged in value from as little as US$32.2211 up to US$38.1993. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NYSE average) beta is 1, while GlaxoSmithKline's is 0.289. This would suggest that GlaxoSmithKline's shares are less volatile than average (for this exchange).
| Revenue TTM | US$29.7 billion |
|---|---|
| Operating margin TTM | 31.37% |
| Gross profit TTM | US$19.9 billion |
| Return on assets TTM | 7.9% |
| Return on equity TTM | 61.26% |
| Profit margin | 20.48% |
| Book value | 3.238 |
| Market capitalisation | US$73.3 billion |
TTM: trailing 12 months
Dividend payout ratio: 36.98% of net profits
Recently GlaxoSmithKline has paid out, on average, around 36.98% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.91% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), GlaxoSmithKline shareholders could enjoy a 3.91% return on their shares, in the form of dividend payments. In GlaxoSmithKline's case, that would currently equate to about $0.558 per share.
While GlaxoSmithKline's payout ratio might seem fairly standard, it's worth remembering that GlaxoSmithKline may be investing much of the rest of its net profits in future growth.
GlaxoSmithKline's most recent dividend payout was on 11 January 2024. The latest dividend was paid out to all shareholders who bought their shares by 17 August 2023 (the "ex-dividend date").
GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is based in Brentford, the United Kingdom.
Looking to jump on the AI bandwagon? Here's how you can invest in ChatGPT and its parent company OpenAI from Australia.
Looking for the best performing stocks in Australia? We update this list weekly.
If you’re looking for ways to gain exposure to Bitcoin and other digital currencies, cryptocurrency ETFs could be worth exploring. Find out what crypto ETFs are and how they work in this introductory guide.
Steps to owning and managing Gol Linhas Aéreas Inteligentes SA shares from Australia.
Steps to owning and managing Microsoft shares from in Australia.
Looking for alternative investments? With a ROI of up to 3,593% lego may be worth considering. Read on to find out which lego sets are worth the investment.
Find cheap stock brokerage in Australia when buying and selling shares on the ASX and other international exchanges.
Learn about the money market and everyday consumer money market products.
Equity crowdfunding offers a unique opportunity for investors and for Australian startups, but Australia’s regulatory framework surrounding crowdfunding still lags behind the rest of the world.
Follow these tips to find the best share trading platform for you.
